MK-2048
- 未分配
- 正在接受调查(2016)
- (6S)-2-[(3-chloro-4-fluorophenyl)methyl]-8-ethyl-9-hydroxy-N,6-dimethyl-1,10-dioxo-6,7-dihydropyrazino[3,4]pyrrolo[3,4-b]pyridazine-4-carboxamide
- 11554427
- 25058456
- ChEMBL1237018
- DTXSID70236031
![編輯維基數據鏈接](http://upload.wikimedia.org/wikipedia/commons/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png)
- 交互式图像
- CCN1CC(N2C3=C(C(=O)C2=C1O)C(=O)N(N=C3C(=O)NC)CC4=CC(=C(C=C4)F)Cl)C
- InChI=1S/C21H21ClFN5O4/c1-4-26-8-10(2)28-16-14(18(29)17(28)21(26)32)20(31)27(25-15(16)19(30)24-3)9-11-5-6-13(23)12(22)7-11/h5-7,10,32H,4,8-9H2,1-3H3,(H,24,30)/t10-/m0/s1
- Key:IOYLKNABOQYKKY-JTQLQIEISA-N
![](http://upload.wikimedia.org/wikipedia/commons/thumb/d/d5/Star_of_life_caution.svg/20px-Star_of_life_caution.svg.png)
MK-2048系第二代整合酶抑制剂,是抗病毒药品,用于对抗HIV感染。其较前代整合酶抑制剂药物拉替拉韦[注 1]的优点是,该药物对HIV整合酶的有效抑制时间长达4倍。MK-2048作为暴露前阻断药物(PrEP)的实用性正在研究当中。[1]
MK-2048由默克藥廠开发。[2]
注释
- ^ 英文:raltegravir,又称MK-0518。商品名为“Isentress”。
参考
- ^ Keith Alcorn. Ralvetgravir shows potential for use as PrEP drug (页面存档备份,存于互联网档案馆) AIDSmap.com. 28 April 2009. Accessed 8 Nov 2009.
- ^ Mark Mascolini. Merck Offers Unique Perspective on Second-Generation Integrase Inhibitor. (页面存档备份,存于互联网档案馆) 10th International Workshop on Clinical Pharmacology of HIV Therapy, April 15–17, 2009, Amsterdam. Accessed 8 Nov 2009.